• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Arcus Biosciences Stock Faces Revenue Drop And Wider Nine Month Loss

    Simply Wall St·11/13/2026 14:20:16
    Listen to the news
    • Arcus Biosciences reported third quarter 2026 revenue of US$9 million compared with US$26 million a year earlier, with a net loss of US$128 million and basic loss per share of US$1 from continuing operations.
    • For the first nine months of 2026, Arcus Biosciences recorded US$67 million in revenue and a US$347 million net loss. This sharpens the focus on how much cash the business is burning while it concentrates spending on late stage oncology programs such as casdatifan.
    • We will now look at how Arcus Biosciences' investment narrative compares with this weaker revenue base and larger year to date loss.

    Broaden your watchlist beyond Arcus Biosciences by scanning a curated set of late stage healthcare and biotech plays in the 35 healthcare AI stocks.

    Arcus Biosciences Investment Narrative Recap

    To own Arcus Biosciences, you need to believe casdatifan and the rest of the oncology pipeline can eventually justify today’s heavy spending. The latest quarter shows US$9 million in revenue and a net loss of US$128 million, so the near term story is still about funding late stage trials rather than commercial returns.

    The key short term catalyst remains progress in casdatifan registrational work, especially around RCC data and trial milestones highlighted in the analyst consensus Narrative on Simply Wall St. The biggest operational risk is the rising year to date loss of US$347 million, which raises the bar on execution even if the quarterly loss did not change dramatically.

    The recent earnings update is the most relevant announcement here. Revenue for the first nine months of 2026 was US$67 million against a year to date loss of US$347 million, so the business is relying on its cash runway and prior equity raise to keep late stage programs moving at full speed.

    This reporting backdrop frames every future catalyst mentioned in the analyst consensus Narrative on Simply Wall St. Plans to focus more than 80% of portfolio spend on casdatifan by 2027 and to complete PEAK 1 enrollment by the end of 2026 require sustained cash discipline. Any further widening of losses or delay in data readouts would amplify that execution risk.

    Arcus Biosciences’ story lines up with analyst models that point to US$263.5 million in revenue and US$48.2 million in earnings by 2029. These projections are built on an assumed 31.1% yearly increase in revenue and an earnings change from a loss of US$460.0 million today to positive earnings in 2029, which represents a very large change in absolute terms.

    Uncover why Arcus Biosciences' fair value indicates a 131% potential upside to its current price that could narrow quickly.

    NYSE:RCUS 1-Year Stock Price Chart
    NYSE:RCUS 1-Year Stock Price Chart

    Exploring Other Perspectives

    Arcus Biosciences looks very different if you focus on the most bearish analysts. They were already modeling revenue drifting to about US$120.2 million by 2028 and only US$17.0 million in earnings, with a 5.2% yearly decline in sales assumed before this earnings release. That view leans heavily on partnership risk and funding pressure, so use it as a counterweight and explore several narratives before deciding how this new report might reshape expectations.

    Explore 2 other Arcus Biosciences fair value estimates, including one that suggests it could be worth just $34.92.

    Decide For Yourself

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Arcus Biosciences?

    Once you have formed a view on Arcus Biosciences, it helps to test your thinking against opportunities in other corners of the market. The Simply Wall St Screener lets you move from a single stock view to a shortlist built around the traits you care about most.